PubRank

Ronald Levy

Author PubWeight™ 138.53‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004 6.91
2 Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003 6.77
3 Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2009 5.84
4 In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010 3.88
5 Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010 3.37
6 Structural organization of bacterial RNA polymerase holoenzyme and the RNA polymerase-promoter open complex. Cell 2002 3.21
7 Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013 2.77
8 Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002 2.52
9 Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 2006 2.32
10 B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A 2010 2.10
11 CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2010 2.06
12 In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2011 2.02
13 Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood 2005 1.99
14 The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2006 1.94
15 Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012 1.92
16 LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2007 1.88
17 Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013 1.86
18 Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009 1.81
19 Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004 1.74
20 A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood 2009 1.74
21 BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 2003 1.73
22 Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 2006 1.72
23 Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma 2009 1.71
24 T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2008 1.69
25 The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002 1.68
26 Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma 2009 1.68
27 Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014 1.58
28 Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A 2003 1.58
29 Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2013 1.55
30 Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008 1.55
31 Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007 1.54
32 Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A 2002 1.49
33 HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 2003 1.47
34 Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011 1.41
35 Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 2002 1.40
36 A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008 1.36
37 Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014 1.29
38 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
39 Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 2008 1.22
40 The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004 1.22
41 Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 2013 1.20
42 Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer 2009 1.19
43 Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma 2002 1.18
44 Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002 1.17
45 Combination strategies to enhance antitumor ADCC. Immunotherapy 2012 1.12
46 High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 2013 1.12
47 Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood 2006 1.11
48 Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. Blood 2006 1.09
49 BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 2002 1.09
50 Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 2009 1.08
51 Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 2008 1.07
52 Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002 1.07
53 Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood 2006 1.00
54 Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. Biotechnol Bioeng 2005 0.99
55 ''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn 2007 0.96
56 A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood 2010 0.96
57 Self-antigen recognition by follicular lymphoma B-cell receptors. Blood 2012 0.95
58 Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma 2009 0.95
59 The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol 2009 0.94
60 Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol 2011 0.93
61 Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 2003 0.92
62 A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. Proc Natl Acad Sci U S A 2012 0.91
63 Cancer vaccines: pessimism in check. Nat Med 2004 0.91
64 Cell-free production of Gaussia princeps luciferase--antibody fragment bioconjugates for ex vivo detection of tumor cells. Biochem Biophys Res Commun 2009 0.90
65 Active and passive immunotherapy for lymphoma: proving principles and improving results. J Clin Oncol 2011 0.90
66 Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res 2005 0.90
67 CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol 2012 0.90
68 Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. Am J Surg Pathol 2010 0.90
69 In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res 2002 0.89
70 Expression of active murine granulocyte-macrophage colony-stimulating factor in an Escherichia coli cell-free system. Biotechnol Prog 2004 0.88
71 Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood 2009 0.88
72 Molecular outcome prediction in diffuse large-B-cell lymphoma. N Engl J Med 2009 0.88
73 Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer Metastasis Rev 2011 0.88
74 Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. Br J Haematol 2008 0.87
75 Idiotype vaccination for lymphoma: moving towards optimisation. Leuk Lymphoma 2009 0.87
76 Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J Immunol Methods 2003 0.87
77 Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. Hematology Am Soc Hematol Educ Program 2000 0.87
78 Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms. Haematologica 2007 0.86
79 Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. Cancer Res 2012 0.86
80 Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst 2003 0.86
81 B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. Blood 2014 0.86
82 Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 2013 0.84
83 TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection. J Immunol 2004 0.83
84 CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol 2009 0.83
85 Cancer vaccines and T cell therapy. Biol Blood Marrow Transplant 2012 0.83
86 Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand. Cancer Res 2007 0.83
87 Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81. Proc Natl Acad Sci U S A 2012 0.82
88 Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma. Am J Clin Pathol 2010 0.80
89 Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. Int J Mol Epidemiol Genet 2011 0.79
90 Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma. Leuk Lymphoma 2002 0.78
91 The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. Am J Clin Pathol 2011 0.78
92 Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma. Protein Expr Purif 2010 0.78
93 C-C chemokine receptor 1 expression in human hematolymphoid neoplasia. Am J Clin Pathol 2010 0.78
94 Diffuse large B-cell lymphoma: insights gained from gene expression profiling. Int J Hematol 2003 0.77
95 Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma. Leuk Lymphoma 2003 0.77
96 Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. Immunotherapy 2009 0.76
97 Profile of Ronald Levy. Interview by Phillip Downey. Proc Natl Acad Sci U S A 2010 0.75
98 Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas. Br J Haematol 2004 0.75
99 Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma. Am J Hematol 2011 0.75